Pharmaceuticals for the imaging of angiogenic disorders

Details Pharmaceuticals for the imaging of angiogenic disorders Pharmaceuticals for the imaging of angiogenic disorders

2006-05-30

2006-05-30

Jones, Dameron L. (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C206S223000, C206S569000, C206S570000, C534S014000, C514S014800

Reexamination Certificate

active

07052673

ABSTRACT:
The present invention describes novel compounds of the formula:in-line-formulae description="In-line Formulae" end="lead"?(Q)d—Ln—Ch,in-line-formulae description="In-line Formulae" end="tail"?useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

REFERENCES:
patent: 4248802 (1981-02-01), Kuntz
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4859777 (1989-08-01), Toner
patent: 4988827 (1991-01-01), Bergstein et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5064956 (1991-11-01), Kruper et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5281704 (1994-01-01), Love et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5350837 (1994-09-01), Bridger et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5395609 (1995-03-01), Stuttle
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5595723 (1997-01-01), Quay
patent: 5650134 (1997-07-01), Albert et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5659041 (1997-08-01), Pollak et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5739789 (1998-04-01), Kronhamn
patent: 5744120 (1998-04-01), Edwards
patent: 5750088 (1998-05-01), Sworin et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5767071 (1998-06-01), Palladino et al.
patent: 5770565 (1998-06-01), Cheng et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6040311 (2000-03-01), Duggan et al.
patent: 6051207 (2000-04-01), Klaveness et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6056973 (2000-05-01), Allen et al.
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6537520 (2003-03-01), Rajopadhye et al.
patent: 6800273 (2004-10-01), Rajopadhye et al.
patent: 2002/0132774 (2002-09-01), Klagsbrun et al.
patent: 2002/0147136 (2002-10-01), Von Wronski et al.
patent: 5314694 (1994-07-01), None
patent: 2 113 245 (1988-06-01), None
patent: 2 039 259 (1991-10-01), None
patent: 2 156 620 (1994-10-01), None
patent: 2 232 315 (1997-04-01), None
patent: 4 311 023 (1994-10-01), None
patent: 19 536 781 (1997-03-01), None
patent: 19 536 785 (1997-03-01), None
patent: 19 725 368 (1998-12-01), None
patent: 0 107 734 (1987-07-01), None
patent: 0 359 347 (1990-03-01), None
patent: 0 436 005 (1991-10-01), None
patent: 0 606 683 (1994-07-01), None
patent: 0 727 225 (1996-08-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 90/93801 (1990-04-01), None
patent: WO 90/05539 (1990-05-01), None
patent: WO 09/12585 (1990-11-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/01144 (1991-02-01), None
patent: WO 91/14460 (1991-10-01), None
patent: WO 91/15244 (1991-10-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 92/17215 (1992-10-01), None
patent: WO 92/19646 (1992-11-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/23074 (1993-11-01), None
patent: WO 94/05328 (1994-04-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 94/22496 (1994-10-01), None
patent: WO 94/22497 (1994-10-01), None
patent: WO 94/22910 (1994-10-01), None
patent: WO 95/25593 (1995-09-01), None
patent: WO 96/00574 (1996-01-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 96/31243 (1996-10-01), None
patent: WO 96/41803 (1996-12-01), None
patent: WO 97/08145 (1997-03-01), None
patent: WO 97/16474 (1997-05-01), None
patent: WO 97/18207 (1997-05-01), None
patent: WO 97/23480 (1997-07-01), None
patent: WO 09/14220 (1998-04-01), None
patent: WO 98/16256 (1998-04-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 99/06049 (1999-02-01), None
patent: WO 99/13329 (1999-03-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/58162 (1999-11-01), None
patent: WO 02/04030 (2002-01-01), None
Ashton, et al.,J. Org. Chem., 1996, 61, 903-908.
Bakker, et al.,Life Sci., 1991, 49, 1583-1591.
Barcelona, E.S., “Cilengitide/oncolytic angiogenesis inhibitor integrin alphavbeta3, alphabeta5 antagonist,”Drugs of the Future, 2000, 7(25), 674-678.
Batt, et al.,J. Med. Chem., 2000, 43, 41-58.
Bevilacqua, et al.,Proc. Natl. Acad. Sci., 1987, 84, 9238-9242.
Bousquet, et al.,Radiology, 1988, 166, 693.
Brechbiel, M., et al.,Bioconjugate Chem., 1991, 2, 187.
Brechbiel, M., et al.,J. chem.. Soc. Perkins Trans., 1992, 1, 1175.
Burke, P.A., et al., “Combined modality radioimmunotherapy/promise and peril,”Am. Can. Soc., Feb. 15, 2002,Suppl. 4(94), 1320-1331.
Burris, et al.,Clin. Can. Res., 1995, 1, 1623-1634.
Burrows, et al.,J. of Controlled Release, Jan. 1994, 28(1), 195-202.
Burrows, et al.,Cancer Res., 1992, 52, 5954-5962.
Burrows, et al.,Proc. Nat. Acad. Sci. USA, 1993, 90, 8996-9000.
Clauss, et al.,J. of Biological Chem., 1990, 265(12), 7078-7083.
DeGrado, et al.,J. Org. Chem., 45, 1295-1300.
Denekamp, J., et al.,Br. J. Cancer, 1982, 45, 136-139.
Denekamp, J., et al.,Br. J. Cancer, 1982, 46, 711-720.
Denekamp, J.,Acta Radiologica Oncology, 1984,23 Fasc. 4, 217-225.
Denekamp, J.,Cancer Meta. Rev., 1990, 9, 267-282.
DeNardo, et al.,Cancer Biotherapy&Radiopharm., Feb. 2000, 15(1), 71-79.
DiZio, et al.,Bioconjugate Chem., 1991, 2, 353-366.
Dvorak, et al.,Cancer Cells, 1991, 3, 77-85.
Folkman, J.,Nature Medicine, 1995, 1, 27-31.
Friedlander, et al.,Science, 1995, 270, 1500-1502.
Ghose, et al.,Meth. Enzymology, 1983, 93, 280-333.
Hagemeier, H.-H., et al.,Int. J. Cancer, 1986, 38, 481-488.
Henry, T., et al.,J. Amer. College Cardiology1998, 31, 65A.
Horton, et al.,Int. J. Biochem. Cell Biol., May 1997, 29(5), 721-725.
Hu, et al.,Oncology Res., 1994, 6(7), 321-327.
Hubbrich, et al.,Liebigs Ann. Chem., 1979, 776-783.
Kennel, et al.,Nuclear Med.&Biol., 1998, 25, 241-246.
Kerr, etal.,Anticancer Res., Mar./Apr. 1999, 19(2A), 958-958.
Knowles, et al.,Analytical Biochemistry, 1987, 160-440-443.
Krenning, et al.,Digestion, 1996, 57, 57-61.
Krenning, et al.,Eur. J. Nucl. Med., 1993, 20, 716-731.
Liu, S., et al., “90Y and 177LU labeling of a dota-conjugated vitorneclin receptor antagonist useful for tumor therapy,”Bioconjugate Chemistry, Am. Chem. Soc., Jul. 2001, 4(12), 559-568.
Liu, et al.,Inorg. Chem., 1999, 38(6), 1326-1335.
Manning, et al.,Tet Lett., 1997, 53, 11937-11952.
Margerstadt, et al.,Magn, Reson. Med., 1986, 3, 808.
Molema, et al.,Biochemical pharm., 1998, 55, 1939-1945.
Mueller, et al.,Proc. Natl. Acad Sci. USA, 1992, 89, 11832-11836.
Nucl. Med., Proceeding of the 42ndAnnual Meeting, May 1995, 36(5), No. 287, 71P.
Olson, et al.,Int. J. Cancer, 1997, 73, 865-870.
O'Reilly, et al.,Cell, 1994, 79, 315-328.
Orlando, et al.,J. of Biological Chem., Oct. 1991, 266(29), 19543-19550.
Runge, et al.,Radiology, 1988, 166, 835.
Seillke, et al.,Drugs, 1999, 58(3), 391-396.
Sipkins, et al.,Nature Medicine, May 1998, 4(5), 623-626.
Takeshima, S., et al.,J. Clin. Invest., 1994, 93,

Affiliated with

Also associated with

Rating

Pharmaceuticals for the imaging of angiogenic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceuticals for the imaging of angiogenic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceuticals for the imaging of angiogenic disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3571971